The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 221-227

  Yang, Xueying ^a   Di, Jing ^a   Zhang, Yang ^a   Zhang, Suning ^a   Lu, Jibin ^a   Liu, Jun ^a   Shi, Wenjun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Molecular mechanisms; Rho kinase

Indexed keywords

CASPASE 3; CASPASE 9; CELL ENZYME; FASUDIL; GELATINASE A; GELATINASE B; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG SMALL CELL CANCER; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; APOPTOSIS; CASPASE 3; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84862832422     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.011     Document Type: Article

References (26)

1. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83:1325-1358.
2. Zicha D., Dobbie I.M., Holt M.R., Monypenny J., Soong D.Y., Gray C., et al. Rapid actin transport during cell protrusion. Science 2003, 300:142-145.
3. Ridley A.J. Rho proteins and cancer. Breast Cancer Res Treat 2004, 84:13-19.
4. Sahai E., Marshall C.J. Rho-GTPases and cancer. Nat Rev Cancer 2002, 2:133-2142.
5. Fritz G., Just I., Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999, 81:682-687.
6. Burbelo P., Wellstein A., Pestell R.G. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 2004, 84:43-48.
7. Ying H., Biroc S.L., Li W.W., Alicke B., Xuan J.A., Pagila R., et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006, 5:2158-2164.
8. Shin J.Y., Kim J.O., Lee S.K., Chae H.S., Kang J.H. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 2010, 10:425.
9. Koul N., Sharma V., Dixit D., Ghosh S., Sen E. Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells. BMC Cancer 2010, 10:328.
10. Chen T., Xu Y., Guo H., Liu Y., Hu P., Yang X., et al. Experimental therapy of ovarian cancer with synthetic Makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One 2011, 6(6):e20729.
11. Sasaki K., Tsuno N.H., Sunami E., Tsurita G., Kawai K., Okaji Y., et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10:370.
12. Levin E.G. Cancer therapy through control of cell migration. Curr Cancer Drug Targets 2005, 5:505-518.
13. Nakajima M., Hayashi K., Katayama K., Amano Y., Egi Y., Uehata M., et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 2003, 459:113-120.
14. Yang X., Liu Y., Zong Z., Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 2010, 64(1):58-62.
15. Yang X., Zhang Y., Wang S., Shi W. The effect of Fasudil on growth, adhesion, invasion and migration of 95-D lung carcinoma cells in vitro. Can J Physiol Pharmacol 2010, 88(9):874-879.
16. Kader A.K., Liu J., Shao L., Dinney C.P., Lin J., Wang Y., et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 2007, 13:2614-2620.
17. Peng Z.M., Tang F.Q., Wu E.S. Study of gene expression difference in lung carcinogenesis by cDNA microarray. Ai Zheng 2004, 23:150-154.
18. Chung A.W., Rauniyar P., Luo H., Hsiang Y.N., van Breemen C., Okon E.B. Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J Vasc Surg 2005, 42:747-756.
19. Gómez-Hernández A., Sánchez-Galán E., Martín-Ventura J.L., Vidal C., Blanco-Colio L.M., Ortego M., et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol 2006, 47:60-69.
20. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
21. Sun G.P., Kohno M., Guo P., Nagai Y., Miyata K., Fan Y.Y., et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006, 17:2193-2201.
22. Takamura M., Sakamoto M., Genda T., Ichida T., Asakura H., Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001, 33:577-581.
23. Wilkinson S., Paterson H.F., Marshall C.J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 2005, 7:255-261.
24. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y., et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003, 9:2632-2641.
25. Sharpe C.C., Hendry B.M. Signaling: focus on Rho in renal disease. J Am Soc Nephrol 2003, 14:261-264.
26. Umeda D., Yano S., Yamada K., Tachibana H. Involvement of 67-kDa laminin receptor-mediated myosin phosphatase activation in antiproliferative effect of epigallocatechin-3-O-gallate at a physiological concentration on Caco-2 colon cancer cells. Biochem Biophys Res Commun 2008, 371:172-176.